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Abstract
Background: People with temporal lobe epilepsy (TLE) report significant problems with learning and memory. There are
no effective therapies for combatting these problems in people with TLE, resulting in an unmet therapeutic need. The
lack of treatment is, in part, due to a poor understanding of the neurobiology underlying these memory deficits. We
know that hippocampal neurogenesis, a process believed to be important in learning and memory formation, is
permanently reduced in chronic TLE, and this may go some way to explain the learning and memory impairments seen
in people with TLE.
The common anti-depressant drug fluoxetine has been shown to stimulate neurogenesis both in the healthy brain and
in neurological diseases where neurogenesis is impaired. In an animal model of TLE, administration of fluoxetine was
found to restore neurogenesis and improve learning on a complex spatial navigational task. We now want to test this
effect in humans by investigating whether administration of fluoxetine to people with TLE can improve learning and
memory.
Methods: This is a single-centre randomised controlled, double-blind feasibility trial. We plan to recruit 20 participants
with a diagnosis of TLE and uni-lateral hippocampal sclerosis, confirmed by 3T MRI. Eligible participants will undergo
baseline assessments of learning and memory prior to being randomised to either 20 mg/day fluoxetine or matching
placebo for 60 days. Follow-up assessments will be conducted after 60 days of trial medication and then again at 60
days after cessation of trial medication. Feasibility will be assessed on measures of recruitment, retention and
adherence against pre-determined criteria.
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Discussion: This trial is designed to determine the feasibility of conducting a double-blind randomised controlled trial
of fluoxetine for the treatment of learning and memory impairments in people with TLE. Data collected in this trial will
inform the design and utility of any future efficacy trial involving fluoxetine for the treatment of learning and memory
in people with TLE.
Trial registration: EudraCT 2014-005088-34, registered on May 18, 2015
Keywords: Temporal lobe epilepsy, Hippocampal sclerosis, Fluoxetine, Allocentric learning
Backgrounds
Epilepsy is the most common chronic neurological dis-
order affecting between 4 and 7 in 1000 people in devel-
oped countries [1]. Temporal lobe epilepsy (TLE) is the
most common form of drug refractory focal epilepsy [2].
It is thought that TLE accounts for up to 40% of all focal
epilepsy diagnoses [3]. In TLE, seizures arise from a
focal point within the temporal lobe and can manifest
with a range of seizure types including simple partial sei-
zures (typically producing an aura or strong emotional
(fear) or physiological (smell) responses), complex partial
seizures (consciousness is altered and repeated move-
ments such as grabbing at clothes or lip smacking are
observed) or secondary generalised tonic-clonic seizures.
In addition to seizures, people with TLE also experi-
ence a number of neuropsychological co-morbidities
with memory dysfunction reported as the most common
neuropsychological effect of TLE [4–6]. Over half of pa-
tients with epilepsy rate their memory problems as mod-
erate to severe [7], contributing significantly to their
adverse quality of life [8] and impacting considerably on
their daily functioning. At present, there are no pharma-
cological or non-pharmacological strategies available to
try and combat the learning and memory problems asso-
ciated with TLE. Indeed, although the neuropsycho-
logical problems associated with chronic epilepsy and
TLE in particular are well documented, there is a dearth
of research into combatting this common issue, thus
highlighting cognitive dysfunction in TLE as a significant
unmet therapeutic need.
In general terms, the cause of epilepsy is poorly under-
stood and cannot be defined for all epilepsy patients.
However, TLE is strongly linked with hippocampal scler-
osis (HS), which describes a general atrophy and scarring
of the hippocampus. This can be either on one (unilat-
eral) or both (bilateral) sides of the brain [9].
The hippocampus is a brain structure known to be im-
portant in all stages of episodic and spatial memory pro-
cessing including encoding, consolidation and retrieval
[10–12]. Spatial learning, to locate a specific target or
goal, is known to employ different strategies as follows:
allocentric learning describes the process by which a
person creates a cognitive map by remembering the
specific spatial relationship between the surrounding en-
vironment and the target, and egocentric learning de-
scribes how a person will learn the spatial relationship
between the goal and their own body. Both rodent [13]
and human studies [14] using the Morris Water Maze
paradigm and functional magnetic resonance imaging
(MRI) [15, 16] have demonstrated that the hippocampus
is necessary for allocentric but not egocentric or cued
learning. This may indicate why patients with TLE have
such problems with spatial learning and memory recall.
Further, we have recently demonstrated that patients
with unilateral HS have significantly less efficient allo-
centric learning than healthy controls [17] and although
this can be overcome by increased training, they also
forget the learned task more quickly.
The hippocampus is a site for adult neurogenesis [18],
the formation of new brain cells in the developed brain.
Although in the past the role of neurogenesis in spatial
learning has been debated [19], paradigms which require
a higher cognitive load (such as allocentric learning)
have identified a significant role for neurogenesis in both
the acquisition [20] and retrieval [21] of spatial memor-
ies. Further, neurogenesis appears to be particularly im-
portant for supporting pattern separation of similar
stimuli [22], which supports allocentric learning.
In animal models status epilepticus permanently alters
hippocampal neurogenesis [23–25]. Not only does status
epilepticus alter the amount of newly formed cells [26]
but also reduces the resultant connectivity of newly born
neurons [27, 28]. Deficits in neurogenesis have been
confirmed in patients with TLE [29] which is associated
with decreased performance in memory and learning
tasks [30]. Thus, impaired neurogenesis may be one pos-
sible biological mechanism that can account for the
manifestation of memory and learning deficits in pa-
tients with TLE. We have validated the kainate model of
mesial TLE in rats, by identifying reduced neurogenesis
and an exactly matching pattern of spatial learning defi-
cits to that seen in patients with hippocampal sclerosis
(virtual water maze) [17, 31].
Rates of neurogenesis can be affected by a number of
different factors including depression [32], stress[33], ex-
ercise [34] and neurotrophic factors [35, 36]. It has now
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been established that pharmacological agents, particu-
larly anti-depressants such as fluoxetine can increase
levels of neurogenesis in rats and primates [37]. Critic-
ally, it has been demonstrated that learning impair-
ments and altered neurogenesis exhibited in the rat
kainate model of TLE can be effectively restored by
fluoxetine treatment [31].
The currently available research evidence strongly sug-
gests that impairment in hippocampal neurogenesis un-
derlies the deficits in allocentric learning seen in
patients with TLE. Further, evidence from animal models
of TLE shows that fluoxetine is effective in improving
neurogenesis sensitive learning [31], which leads to the
question, can fluoxetine treatment enhance adult human
neurogenesis and thus improve learning and memory
deficits in people with TLE and HS?
Fluoxetine is a relatively cheap, widely available and
generally well-tolerated medication with a good safety
profile, and is widely prescribed in people with epilepsy
[38], owing to the high comorbidity of depression and
epilepsy [39]. Whilst the British National Formulary
(BNF) urges caution for the prescription of fluoxetine in
this population based on experimental increased seizure
risk [40], most studies suggest the anti-depressants do
not worsen seizures and may have a protective, anti-
convulsant effect at therapeutic doses [41–46]. Further,
there is evidence to suggest that fluoxetine can increase
suicidal thoughts and suicidal ideation in adolescents
[47–49], but this is only in people being treated for ac-
tive ongoing depression. Whilst these factors pose a po-
tential risk, it is possible to mitigate these risks, and
thus, fluoxetine treatment in the context of remedying
an unmet therapeutic need in people with TLE warrants
further investigation.
Learning and memory in people with TLE can be mea-
sured using a number of hippocampal-dependent mea-
sures of learning. This includes the virtual water maze (a
direct correlate of the widely used rodent version and
described in [17]), pattern separation tasks and Sense-
Cam paradigm. Pattern separation tasks serve as a highly
hippocampal-dependent test of location memory that
can be automated in both rodent [50] and human [51]
models of testing. There is evidence to suggest that dis-
crimination of pattern separation, especially when finely
spaced, is dependent on neurogenesis [52]. The SenseCam
paradigm allows the testing of learning and memory in a
real-world setting which may be more applicable to situa-
tions of daily living where memory deficits may be more
problematic. This has previously been used to demon-
strate accelerated forgetting in people with transient epi-
leptic amnesia [53].
Here, we describe a feasibility trial to see if the investi-
gation of the beneficial effects of fluoxetine treatment in
animal models of epilepsy can be successfully translated
into the human epilepsy population, to assess its poten-
tial as an effective therapy for the memory and learning
impairments associated with TLE. This feasibility trial
will allow us to examine a number of trial processes
such as recruitment, retention and adherence of trial
participants and to calculate potential effect sizes on
outcome assessments for designing an appropriately
powered phase II efficacy trial to determine if fluoxetine
has any beneficial effects on the learning and memory of
people with TLE.
Methods
Trial design and setting
FLAME is a single-centre, double-blind, randomised
placebo-controlled feasibility trial of the effect of fluoxetine
on learning and memory deficits in patients with TLE. All
research activities will be conducted between University
Hospital Wales, Cardiff, and clinical research facilities
within Cardiff University. Eligible participants will perform
baseline cognitive assessments prior to randomisation to
trial treatment or placebo. Following randomisation on the
last day of the baseline assessments, participants will com-
mence study treatment and after a treatment period of 60
days, the cognitive assessments will be repeated whilst con-
tinuing the trial medication. Participants will cease trial
medication at the end of follow-up assessment one and will
begin a washout period of 60 days, after which they will
complete the final battery of cognitive assessments at
follow-up assessment 2 (Fig. 1).
Primary objective
The primary objective of this trial is to determine the
feasibility of conducting a double-blind, randomised
controlled trial of the effect of fluoxetine on learning
and memory in people with TLE.
Secondary objectives
Secondary objectives of this trial are largely exploratory
and are to (1) determine the effect of 60 days of oral fluox-
etine treatment on spatial and verbal learning in people
with TLE and any ongoing effects after a further 60 days
of treatment withdrawal, (2) determine if people with TLE
differ in the severity of their learning deficit dependent on
which side hippocampal sclerosis occurs, (3) determine if
people with TLE show a deficit in pattern separation and
if these deficits can predict a response to fluoxetine, (4) in-
vestigate if hippocampal microstructure correlates with
allocentric learning and memory deficits and/or the re-
sponse to fluoxetine and (5) determine if fluoxetine alters
the seizure frequency of people with TLE.
Recruitment and consent
We aim to recruit 20 participants for this trial; ideally 10
people with right-handed HS and 10 people with left-
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handed HS. The sample size was set at the maximum
that was deemed achievable within the timeframe and
budget of the study and given the size of the target
population and level of engagement required. It will
allow us to estimate the recruitment, retention and ad-
herence rates with 95% confidence intervals of no more
± 22 percentage points. Potentially eligible participants
will be identified from epilepsy clinic lists within the
Alan Richen’s Epilepsy Unit in University Hospital
Wales, Cardiff, and associated clinical databases. Add-
itional participant identification centres (PICs) will be
used across South Wales, Bristol and Southampton. Po-
tentially eligible participants will either be sent an invita-
tion letter with the participant information sheet (PIS)
or will be handed the PIS during their routine clinic
visit. Along with the PIS, participants will also be given a
contact form on which they can indicate their interest,
in participating in the trial along with contact details
enabling a researcher to contact them. The trial will also
be externally advertised on third sector websites such as
Epilepsy Action to allow for participant self-referral.
Those participants that return the contact form or
otherwise indicate their willingness to participate will be
asked to provide written consent. Consent will be taken
by trained and qualified trial researchers.
Additionally, we will seek to recruit a family member or
care giver for each participant recruited who can accom-
pany them to assessments. These additional recruits will act
as controls for one of the cognitive assessments employed
(SenseCam). Full written consent will be also obtained from
healthy controls prior to their inclusion in the trial.
Inclusion/exclusion criteria
The inclusion/exclusion criteria have been selected on
the basis of what we believe would be required for an ef-
ficacy trial. To ensure eligibility for study recruitment,
participants must fulfil all the inclusion criteria as fol-
lows: (1) aged between 18 and 65 years, (2) confirmed
clinical diagnosis of TLE, (3) unilateral HS confirmed by
3T MRI (to enable investigation of potential differences
between right- and left-handed HS) and (4) prepared to
take adequate contraception for the duration of the trial.
Participants will be excluded if they meet any of the ex-
clusion criteria as follows: (1) bi-lateral HS; (2) presence
of significant active anxiety or depression (indicated by a
score of 11 or more on the Hospital Anxiety and De-
pression Scale (HADS) [54]) because an ongoing depres-
sive or anxious state may affect performance on the
behavioural tests included in this study, which could
lead to difficulties in determining whether any change in
outcome measures following fluoxetine treatment,
should they occur, were due to treatment of depression/
anxiety or the effects of fluoxetine on hippocampal
neurogenesis; (3) current treatment with a selective sero-
tonin re-uptake inhibitor (SSRI), as participants would
already be receiving the intervention (4) lacking capacity
or an Intelligence Quotient (IQ) of less than 75 (assessed
by the Wechsler Abbreviated Scale of Intelligence
(WASI-II) [55]); and (5) presence of poorly controlled
seizures in participants undergoing active anti-epileptic
drug (AED) changes, as it known that ongoing seizures
may affect cognition directly.
The remaining exclusion criteria are included for
safety purposes of study assessments or prescription of
fluoxetine: (6) not suitable for MRI; (7) pregnancy or
breastfeeding; (8) participation in another clinical trial of
an investigational medicinal product; (9) previous ad-
verse reaction to fluoxetine; (10) taking any contraindi-
cated medication detailed in the Summary of Product
Characteristics (SPC) (such as monoamine oxidase in-
hibitors); (11) hepatic impairment defined by liver en-
zymes elevated to 2.5 times the upper limit of the
Fig. 1 Schematic of trial design
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normal range; (12) congenital long QT syndrome or any
family history of any clinical condition predisposing to
arrhythmia; (13) taking tamoxifen; and (14) taking St.
John’s wort (as this also alters neurogenesis and the be-
havioural responses to chronic stress [56]).
Participants with a diagnosis of TLE as suggested by
electroencephalography (EEG) recording without con-
firmation of HS on MRI will not be included as epilepti-
form discharges seen on EEG commensurate with a
diagnosis of TLE cannot be localised to the mesial tem-
poral lobe with a high degree of accuracy and may ori-
ginate in the neocortex. As the rationale for this study is
intrinsically linked to potential deficits of neurogenesis
in the hippocampus, participants without confirmation
of HS on MRI will be excluded. This also applies to par-
ticipants who may have bi-lateral EEG signs of TLE but
only uni-lateral HS on MRI.
Screening assessments
Potentially eligible participants will be invited to attend
a screening assessment. This will include a medical his-
tory, blood tests for liver enzymes and electrolytes, com-
pletion of the HADS, completion of the WASI and a
structural 3T MRI to confirm laterality of HS (see Table
1). Any participant who declares a history or family his-
tory of heart conditions predisposing to arrhythmia will
also receive an electrocardiogram (ECG). Participants
who are found to have any of the following, bi-lateral
HS, an intelligence quotient (IQ) of 74 or below, a
HADS score of 12 or more, an aspartate transferase level
more than 2.5 times the upper limit of normal, hypokal-
emia, hypomagnesia or an abnormal ECG (Q-T interval
prolongation, ventricular arrhythmia or Torsades de
pointes), will be excluded from the trial. As the HADS
is a guideline rather than absolute measure of anxiety
or depression, participants who score 11 (borderline)
will undergo review by a consultant psychiatrist. If
the psychiatrist does not think that the participant
has active ongoing anxiety or depression, they will be
able to continue in the trial.
Trial assessments
Participants will be asked to perform a number of written
cognitive tests at baseline only; the purpose of which is to
compare participant performance in novel tests against
standard tests of cognition at baseline and identify poten-
tial floor or ceiling effects. These include the Test of Pre-
Morbid Functioning (TOPF) [57], the Brain Injury Re-
habilitation Trust Memory and Information Processing
Battery (BMIPB) [58] and the Everyday Memory Ques-
tionnaire (EMQ) [59]. Participants will also be asked to
complete the Chalfont Seizure Severity Scale [60].
Table 1 Schedule of trial assessments
Procedure Schedule
Eligibility assessment Baseline
assessments
Study drug Follow-up assessment 1 Follow up assessment
2
Visit number 1 2 3 4 5 6 7 8 9 10 11
Time-point of visit T-1 to 4 weeks T0 T1 T-21 T22-T104 T83 T84 T[97-104] T104 T164 T165 T185
Written informed consent X
HADS X
WASI X
Blood tests (liver function, electrolytes) X
ECG (where indicated) X
MRI Safety Questionnaire X X
Issue of seizure diary X
Structural MRI X X
Review of seizure frequency X X X X X X X X X
QOLIE-31 X X X
Written Cognitive Assessments X
Virtual Water Maze Task X X X X X X X X X
Pattern separation task X X X
Word Lists X X X X X X X X X
Medical Outcomes Sleep Survey X X X
Issue of SenseCam X X X
Testing of SenseCam X X X X X X X X X
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For testing time-point (baseline, follow-up one and
follow-up two), participants will be asked to perform a
series of memory and learning tasks (Table 1). Addition-
ally, they will be asked to complete the shorter version
of the Quality of Life in Epilepsy Questionnaire (QOLIE-
31) [61] and the Medical Outcomes Sleep Survey [62] to
assess whether any observed alterations in sleep quality
relating to fluoxetine mediate any potential effects on
learning and memory. The cognitive tests include the
virtual water maze [17, 31], a pattern separation task
[51], SENSE-CAM task [53] and verbal learning and
memory testing using word lists.
The virtual water maze is a computer generated, the
four-walled room containing a pool which can be navi-
gated by the participant using the arrow keys on a key-
board [17, 31]. An escape platform is located within the
pool and participants must navigate to this escape plat-
form. Participants will be given 50 trials to practise navi-
gating the arena. Participants will receive two sessions;
in the first, they will learn the cued navigation and allo-
centric learning tasks (testing day 1 only) and the second
session will be a probe trial to test the participant’s
learning. Session 2 will be repeated on days 1, 2 and 21
of each testing block. In the initial cued navigation task,
participants must navigate to a visible platform within
the arena from a wall facing starting position. If they do
not locate the platform within 45 s, the researcher will
demonstrate how to reach the platform. This is repeated
for a total of six times, after which, the platform is re-
moved and participants are asked to navigate towards
where they think the platform is (they are told it is now
invisible). The participant’s navigational pathway will be
analysed to determine the amount of time spent in each
quadrant, the latency and distance travelled to cross the
platform area and the number of times they cross the
platform location. In the allocentric task, participants
are placed in the same arena, but this time with external
wall cues. Participants are asked to navigate to an invis-
ible escape platform in the pool within 45 s. Once this is
achieved, they receive an on-screen alert to tell them
they have successfully found the location of the platform
and are given 5 s to view their position in relation to the
external cues. This trial is repeated 20 times with the lo-
cation of the platform remaining constant throughout
but with the start position varied. At the end of the
training, participants are subjected to a probe trial where
the platform has been removed without their knowledge.
The participant’s movements are traced for 45 s to rec-
ord measures of navigation as in the cued navigation
task. Following the probe trial, participants are given
three more training trials as before to lessen the impact
of the probe trial on their memory of the platform loca-
tion. The second session is designed as a test of acceler-
ated forgetting. Participants will be asked to navigate to
the invisible platform, located in the same position as in
session 1. The first trial will be a probe trial, with the
platform removed unbeknownst to the participant and
will last for 45 s. This will then be followed by three fur-
ther training trials to minimise confusion from the pre-
ceding probe trial.
For the pattern separation task, participants enter a
computer-generated arena facing a particular direction
and are then presented with a visual stimulus located in
one of 20 pre-determined spatial locations within the
arena. The participant must then navigate to the stimu-
lus using the arrow keys on a keyboard, and once at the
stimulus, they must press the space bar to initiate the
next part of the trial. For the choice phase, the partici-
pant is presented with four visual stimuli in a square for-
mation; one corner is in the same spatial location as the
previous stimulus and the other three stimuli are foils.
The participant must navigate to the stimulus presented
in the location of the original stimulus using extra-arena
cues and press the space bar to indicate their choice
within the 45 s time limit of the trial. Across trials, three
separation distances between the grouped stimuli will be
used (minimum, intermediate and maximum) in a
pseudorandom order. Twenty-one test pairs (seven per
condition) will be presented in total.
In the SenseCam task, participants will be asked to at-
tend a local tourist attraction, accompanied by a family
member or friend, who has given their consent to par-
ticipate, whilst wearing a SenseCam camera which hangs
around the neck at chest level. Following the excursion,
the researcher will extract 4–5 snapshot images of six
events in order to test the participant’s recall of the ex-
cursion. The person accompanying the participant will
be presented with the same images and asked to recall
details of the excursion in the same manner to provide
control responses to those of the participant. Images will
be presented on a laptop screen and participant will be
given as long as they like to look at the image. They will
be asked to recall the event pictured and secondary de-
tails associated with it—the events occurring either im-
mediately before or after the presented event. Each
correct recollection is given a one-point score giving a
maximum possible score of 3 per picture presented. Par-
ticipants will be tested on their recall on day 1, day 2
and day 21 of each testing block.
Verbal learning and memory will be tested with simple
word lists generated from the MRC Psycholinguistics
Database with the following word characteristics: letters
= 4–6, concreteness = high [500–700], written frequency
= low [1–50] (see [63]). Participants will be given a list
of 20 words and they will be allowed to learn the words
until they can accurately recall 80% of the list provided.
Participant’s recall will then be re-tested after a 30-min
delay on day 1, a 24-h delay on day 2 of the testing block
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and after a 3-week delay on day 21 of the testing block.
On day 21, participants will also be assessed for residual
memory through a recognition test of the original word
list. They will be presented with a set of words containing
some of the original words on the learned list (targets)
and novel words (foils) in equal numbers and asked to
identify the target words. For words that the participant
identifies as one of the target words, they will then be
asked to indicate whether (1) they could recollect any de-
tails about the presentation of the word (“Remember” re-
sponses), or (2) they judged the word to have been a
target but could not recollect any details about its presen-
tation (“Know” responses). The proportion of Remember
and Know responses obtained through this Remember/
Know procedure will then be used to derive estimates of
recollection and familiarity [64, 65].
A 3T MRI will be performed at the screening assess-
ment and will be repeated following trial treatment. The
scanning protocol will include structural sequences re-
quired to confirm unilateral sclerosis (FLAIR as well as
T1- and T2-weighted images), as well as a multi-shell
diffusion-weighted sequence with which we will be able to
derive voxel-wise maps of water diffusion indices. These
will include diffusion tensor MRI (DT-MRI) measures
such as fractional anisotropy (FA) and mean diffusivity
(MD), which are sensitive to grey and white matter micro-
structural abnormalities in a variety of neurological condi-
tions including temporal lobe epilepsy [66–68]. These
measures can be extracted from specific regions-of-
interest (ROIs) and compared pre- versus post-treatment
to test whether fluoxetine treatment affects grey and/or
white matter tissue microstructure (e.g., in the hippocam-
pus and its associated white matter pathways). With these
measures, we can also examine whether performance in
the cognitive tasks is associated with DT-MRI measures in
the same ROIs. Prior to receiving an MRI, participants will
be required to complete a questionnaire to ensure that it
is safe for them to have the scan.
All participants will be provided with seizure diaries at
the start of the baseline assessments. They will be asked
to record any seizures in the diary until they complete
the final follow-up assessment. This diary will be
reviewed at each follow-up and testing session to ensure
that seizure frequency has not increased significantly.
Randomisation, allocation concealment and blinding
Eligible participants will be randomised in a 1: 1 ratio
(fluoxetine to placebo) using random permuted blocks,
stratified by status of laterality of HS (left versus right)
following baseline assessments. Each block of allocations
will be equally balanced between active and placebo. A
computer-generated sequence will select which permu-
tation to use for every block of participants. Block size
and permutations will remain concealed to the trial
team. The trial treatment will be dispensed by the local
clinical trial pharmacy according to the pre-specified list
provided by the trial statisticians. Identical capsules con-
taining either fluoxetine or placebo will be packaged in
identical high-density polyethlyene containers with tam-
per evident closure. Each package will be labelled in
compliance with Annex 13 and according to EU man-
dated Good Manufacturing Practice. A detachable tear
off section will allow maintenance of blinding at the
point of dispensation. Details of allocation will be kept
within the participant accountability records within
pharmacy and will not be revealed to the trial team un-
less emergency unblinding is required. Unblinding will
be permitted if the participant (1) withdraws due to a
significant decrease in mood, (2) exhibits an episode of
status epilepticus, (3) experiences severe withdrawal
symptoms and (4) requires the prescription of any medi-
cation that should not be taken in conjunction with flu-
oxetine as detailed in prescribing guidelines. If any of
these criteria are met, the information will be passed to
the chief investigator (CI) or clinically qualified delegate
who will confirm the need for unblinding. The CI or
trial manager will contact the dispensing pharmacy to
review the accountability records for that participant. In
emergency situations, the CI or clinically qualified dele-
gate will contact the on-call pharmacist to review the
relevant participant accountability log.
Trial treatment
Following randomisation, participants will be allocated
to receive either 20 mg fluoxetine per day or matched
placebo. Fluoxetine will be obtained from Bristol La-
boratories and over encapsulated at St. Mary’s Pharma-
ceutical Unit, Cardiff. Placebo to match will be
manufactured in identical capsules using maize-based
cellulose as the capsule filler. The fluoxetine or placebo
capsules are taken orally once daily for a total of 81 days;
60 days of treatment followed by a further 21 days whilst
the first follow-up assessments are conducted to prevent
confounding effects of washout at the 21-day test point
owing to the short half-life of fluoxetine [69]. Partici-
pants will be asked to bring trial medication with them
to each study visit where study researchers will perform
pill counts for assessing adherence. Adherence will be
measured by recording the number of pills returned and
using this in conjunction with the number of doses sup-
plied to calculate a percentage of the number of doses
that should have been taken in the observed period. Al-
though we will specifically be excluding participants with
active depression, due to the risk of fluoxetine treatment
increasing suicidal thoughts and suicidal ideation in ado-
lescents [47–49], we will perform remote checks on the
mental health on participants. This will be done via a
telephone call with an experienced specialist epilepsy
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nurse 2 to 3 weeks after commencing treatment, when
the risk is at its highest. Any participant indicating
thoughts of suicide or depressive behaviour will be re-
ferred to the trial psychiatrist for immediate follow-up.
The dose chosen for the trial was on the basis of an
equivalent dose being efficacious in animal models [31]
and because it is below the limit at which tapering is re-
quired for medication withdrawal [70, 71], so participants
will not receive tapered doses at the end of the treatment
period or if cessation of trial treatment is required. If a
participant who has stopped the trial treatment experi-
ences any symptoms of withdrawal, they will be unblinded
so that if they received fluoxetine, treatment can be re-
sumed and gradually reduced over 1–2 weeks.
Participants will not be able to take any of the medi-
cines listed in the exclusion criteria for the duration of
the trial, but they will be permitted to continue with
their current AED regime. Participants currently on
carbamazepine therapy will be cautioned to self-monitor
for exacerbation of drug side effects.
Safety
Participants will be monitored for adverse events (AE)
for the duration of the trial. Researchers will prompt
participants to recount any adverse events experienced
at each follow-up visit. Participants will also be encour-
aged to contact the team directly in between follow-up
visits to report any incidence of AE to the trial team by
the use of a trial-specific phone number monitored 24 h
a day. Any AE that meets the criteria for a serious event
will be reported immediately, and causality and expect-
edness will be assessed according to the Summary of
Product Characteristics. We will forward standard time-
lines and procedures for the reporting of serious events
to regulatory authorities.
Feasibility outcomes
The primary outcome of this trial is feasibility which will be
assessed by looking at measures of recruitment (number of
participants recruited, percentage of people approached
willing to participate and percentage of participants to pass
screening), retention (percentage of participants still on
study medication at follow-up assessment one and percent-
age of partially active participants at follow-up assessment
one) and adherence (to study medication) according to pre-
specified criteria, the detail of which can be found in Table
2. Each criterion is stratified into green (feasibility clearly
demonstrated), amber (feasibility possibly demonstrated
but requires further consideration) and red (feasibility not
demonstrated). All criteria would need to be determined to
be green or amber to progress to a full efficacy trial without
major re-design of the study.
Secondary outcome measures
The secondary outcome measures will include the
participant’s performance in all cognitive assessments,
performance in pattern separation task, hippocampal
microstructure (as measured on 3T MRI) and seizure fre-
quency. Learning and memory outcomes will be assessed
across spatial, visual and verbal domains. The spatial do-
main will be assessed using the distance travelled and la-
tency to find the hidden platform in the virtual water
maze. Performance during probe trials will be measured
using the proportion of time participants spend searching
in the four quadrants of the pool and the platform area,
the latency and distance travelled to cross the platform
area, and the number of times the platform area was
crossed. The visual domain will be assessed by using the
recall accuracy of images recorded using the SenseCam
wearable camera (scores), and the verbal domain will be
assessed using word list learning and delayed recall scores.
For the pattern separation task, performance will be
determined by the ratio of correct to incorrect responses
and response latencies. Measures of hippocampal micro-
structure will be derived from diffusion-weighted MRI
acquired before and after trial treatment. Seizure fre-
quency will be determined from the analysis of events
recorded in participant’s seizure diaries.
Table 2 Progression criteria for assessing feasibility of trial design
Variable Progression criteria
Red Amber Green
Recruitment Percentage of participants approached willing to participate < 5% 5–20% > 20%
Percentage of participants screened actually recruited < 50% 50–75% > 75%
Number of participants recruited < 8 8–16 > 16
Number of participants recruited within timeframe (1 year) < 2 2–15 > 15
Retention Percentage of participants still on study medication at follow-up assessment 1 < 30% 30–60% > 60%
Percentage of partially active* trial participants at follow-up assessment 1 < 50% 50–80% > 80%
Percentage of partially active trial participants at follow-up assessment 2 Not subject to progression criteria
Adherence Pill count (compliance) over 81 days < 50% 50–80% > 80%
*This would include participants that have partially withdrawn from the study, for example, stopping study medication but continuing with follow-up assessments
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Qualitative interviews
To gain a better understanding of factors influencing the
participation of people with TLE in a trial such as this,
we will be conducting semi-structured interviews with a
variety of stakeholders. Interviews will be conducted
with full written informed consent with (1) participants
who agreed to take part in the trial, including those who
were deemed to be ineligible; (2) participants who were
invited to take part and declined; and (3) clinicians in-
volved in the identification and recruitment of partici-
pants. We will aim to interview 15–20 people who have
given written, informed consent to gain a wide range of
views and opinions. Interviews will be conducted in a
place of the participant’s choosing, which could include
telephone interviews. Interviews will be audio recorded
and transcribed verbatim for analysis.
Data management and monitoring
All participants recruited to the trial will receive a
unique participant identification number (PID) which
will be used to anonymously identify all files and study
materials relating to them. Personal identifiable data re-
quired for scheduling assessments will be stored in a
password-protected database, separate from the main
trial database on a securely networked computer and ac-
cessible only to the trial manager and CI.
For all standard cognitive assessments and validated
rating scales, data will be collected in the appropriate
published booklet and data entered into the on-line trial
database. Questionnaire data will be collected via elec-
tronic case report forms (CRFs) allowing direct entry
into the database. The computer-based cognitive assess-
ment will automatically collect the required data, and
the summary variables required for each test will be en-
tered into the trial database. For all assessments, paper
CRFs are available for recording data for circumstances
where the trial database may be off-line. The trial data-
base is held on securely networked servers with auto-
matic backup. It is tested and validated with in-built
range checks to ensure the accuracy and validity of data
at the point of entry. All procedures for handling and
storing both electronic and paper records are detailed in
the trial data management plan.
Data will be monitored centrally on a routine basis and
any queries raised directly with trial researchers. These will
be monitored monthly by the trial management group.
Trial steering (TSC) and data monitoring committees
(DMC), independent of the trial sponsor, will be convened
at regular intervals throughout the course of the trial. The
DMC will review period safety data (unblinded if requested)
and report any concerns to the TSC. If there are concerns
that there is a clinically important difference in serious AE
rates between study arms, then the TSC can make a deci-
sion to terminate the trial early with input from the DMC.
Analysis
As this is a feasibility trial, no formal hypothesis testing
will be conducted. The components of the primary out-
come (recruitment, retention, adherence) will be pre-
sented as numbers and/or percentages, as appropriate,
and assessed against pre-specified progression criteria
(Table 2). All secondary outcomes will be summarised
descriptively, by treatment arm. Categorical data will be
summarised by number and percentage. Continuous
data will be summarised by mean and standard devi-
ation, or median and interquartile range if notably
skewed. For each outcome, the relevant complete case
population will be used, and participants will be analysed
as randomised (intention-to-treat). Details of the analysis
are specified in the trial statistical analysis plan.
For the qualitative interviews, transcribed interviews will
undergo manual analysis to identify themes within the
data using NVivo software. Identified themes will be used
to categorise and summarise participant responses. A pro-
portion of interviews (10%) will be randomly selected for
double coding to ensure all relevant data is captured.
Discussion
This feasibility trial is the first step towards determining
the efficacy of fluoxetine as a treatment for the learning
and memory problems associated with TLE [6]. The ul-
timate goal for the study is to see if a larger, fully pow-
ered efficacy trial investigating fluoxetine as a
therapeutic agent for learning and memory problems in
TLE is feasible and warranted.
This trial is designed to gather information on potential
effect sizes in novel cognitive assessments translated from
work in animal models of TLE and cognition. Further, we
will be gathering information on the utility of relatively
novel cognitive testing paradigms. Validation of such out-
come measures could have wide-reaching implications for
the study of cognition and in the investigation of novel
therapies to improve learning and memory in epilepsy and
other neurological disorders and represents a particular
strength of this work. The investigation of fluoxetine in
this context may also provide mechanistic insights into
human adult cognition and the role of neurogenesis
therein, albeit as an indirect measure as changes to human
adult neurogenesis cannot be quantified. The purposeful
exclusion of participants with active depression or anxiety
has been incorporated into the study design to eliminate,
as far as possible, the possible confounding effects of de-
pression and anxiety on cognitive performance in the par-
ticipants studied as depression status and cognitive
performance are interlinked [72]. However, due to the
high prevalence of depression and anxiety in people with
epilepsy [73], this could have profound effects on recruit-
ment rates and overall generalisability of this study, which
is a limitation of the work.
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The MR images captured as part of this study will be
used to investigate whether fluoxetine treatment affects
diffusion MRI measures of tissue microstructure in the
hippocampus and/or its associated white matter path-
ways. To the best of our knowledge, this type of analysis
has not been reported previously and is highly novel.
Whilst this technique cannot directly measure any po-
tential increase in neurogenesis, it will be interesting to
see if fluoxetine treatment has any direct effect on hip-
pocampal microstructure. We will also be able to inves-
tigate any structure-behaviour correlations between
hippocampal microstructure metrics and performance in
our cognitive tasks.
The findings of this trial will advance current know-
ledge in terms of understanding how fluoxetine is toler-
ated in people with epilepsy. The effect of fluoxetine on
seizure frequency is still debated [35–39], so the tracking
of seizure frequency in participants of this trial will pro-
vide further information for epilepsy clinicians con-
cerned about prescribing fluoxetine to their patients.
A particular strength of this study will be realised
through obtaining the views and opinions of participants
taking part and perhaps, more importantly, those who
chose not to take part in the trial will contribute to the
understanding of potential barriers of facilitators under-
pinning the participation of people with epilepsy in this
trial. Further, this information may also contribute to the
understanding of why people with epilepsy may or may
not take part in research and clinical trials in general,
providing valuable information for the future develop-
ment of research studies involving people with epilepsy.
Participants receiving the intervention in this trial have
the potential to benefit from improved learning and
memory using a relatively, cheap, widely available and
generally well-tolerated medication, which may improve
quality of life in people with TLE [8]. This could also
have further societal benefits by reducing demand on
carers and further enabling people with TLE to have ac-
tive and productive working lives.
Trial status
The trial is sponsored by Cardiff University (resgov@cardiff.
ac.uk) and is currently open to recruitment. This manu-
script was drafted according to version 8.0 (December 18,
2018) of the protocol. The protocol was written according
to the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) statement [74].
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